AcelRx Pharmaceuticals, Inc. ACRX Securities Lawsuit

- by

Company: AcelRx Pharmaceuticals, Inc.
Ticker Symbol: ACRX
Class Period: Dec-2-13 to Sep-25-14
Date Filed: Oct-3-14
Lead Plaintiff Deadline: Dec-2-14
Court: Northern District of California
Los Angeles, CA: A securities class action lawsuit has been filed on behalf of purchasers of the common stock and call options and seller of put options of AcelRx Pharmaceuticals, Inc. (Nasdaq:ACRX) during the period from December 2, 2013 through September 25, 2014. The lawsuit seeks to recover investors' losses by asserting claims under the federal securities laws. No class has yet been certified.

The lawsuit alleges that defendants made false and/or misleading statements concerning its Zalviso system pain management product. In particular, the complaint alleges that: (1) the Instructions for Use (IFU) for Zalviso were not designed to adequately address the risk of the accidental misplacement of tablets; (2) AcelRx had not submitted to the FDA sufficient data to support the shelf life of Zalviso; and (3) as a result of the foregoing, AcelRx's statements concerning Zalviso, including the drug's regulatory approval and financial prospects, were materially false and misleading.

On July 25, 2014 AcelRx announced that it had received a Complete Response Letter ("CRL") from the FDA regarding its New Drug Application for Zalviso. The FDA requested additional information on the Zalviso System to ensure proper use of the device, including changes to the Instructions for Use for the device and additional data to support the shelf life of the product. This news caused shares of AcelRx to decline $4.44/share, or 40%, the next trading day.

Then when AcelRx disclosed on September 26, 2014 that the resubmission process for its Zalviso NDA would not be complete until the first quarter of 2015, and that the planned resubmission will have a review period of six months, shares of AcelRx declined $1.31/share, or over 19%, causing investors substantial losses.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

AcelRx Pharmaceuticals, Inc. ACRX Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible AcelRx Pharmaceuticals, Inc. securities class action lawsuit. Please click the link below to submit your complaint for a free evaluation.

Maybe it's your stockbroker

Add Your Comment on This Issue

Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.

*Your Comment:
Request Legal Help